Roch Doliveux, chief executive at UCB, has been appointed chairman of the Innovative Medicines Initiative, the public-private partnership between the European Union and the sector's European Federation of Pharmaceutical Industries and Associations.
Mr Doliveux, who is also on the board at EFPIA, said the biopharmaceutical industry "has reached an inflection point where public-private partnerships, bringing academic and industry knowledge together, are paving the way to better respond to new healthcare needs". He added that EFPIA considers IMI as "a key instrument to implement the new business models which will ensure the sustainability of the pharmaceutical industry and increase the wellbeing of patients across Europe".
Michel Goldman, IMI's executive director, said Mr Doliveux will be "in a
unique position to move forward his vision for the future of the
pharmaceutical industry based on open innovation and precompetitive
research". He added that "the early achievements of the ongoing IMI
projects demonstrate that this new model based on public-private
partnership is already successful".
IMI currently funds 30 projects with a combined budget of around 600
million euros, These cover drug safety and efficacy and knowledge
management, plus education and training.